WEBVTT
Kind: captions
Language: en

00:00:03.440 --> 00:00:06.019
alopecia areata is an autoimmune form of

00:00:06.019 --> 00:00:06.029
alopecia areata is an autoimmune form of
 

00:00:06.029 --> 00:00:08.450
alopecia areata is an autoimmune form of
hair loss where T cells attack the

00:00:08.450 --> 00:00:08.460
hair loss where T cells attack the
 

00:00:08.460 --> 00:00:10.400
hair loss where T cells attack the
growing hair follicle it is not a

00:00:10.400 --> 00:00:10.410
growing hair follicle it is not a
 

00:00:10.410 --> 00:00:12.770
growing hair follicle it is not a
life-threatening form of autoimmunity

00:00:12.770 --> 00:00:12.780
life-threatening form of autoimmunity
 

00:00:12.780 --> 00:00:15.259
life-threatening form of autoimmunity
however it is a life altering form of

00:00:15.259 --> 00:00:15.269
however it is a life altering form of
 

00:00:15.269 --> 00:00:16.250
however it is a life altering form of
autoimmune disease

00:00:16.250 --> 00:00:16.260
autoimmune disease
 

00:00:16.260 --> 00:00:19.010
autoimmune disease
it affects patients in a very profound

00:00:19.010 --> 00:00:19.020
it affects patients in a very profound
 

00:00:19.020 --> 00:00:21.560
it affects patients in a very profound
and very personal way to undergo hair

00:00:21.560 --> 00:00:21.570
and very personal way to undergo hair
 

00:00:21.570 --> 00:00:23.540
and very personal way to undergo hair
loss I could say that with authority

00:00:23.540 --> 00:00:23.550
loss I could say that with authority
 

00:00:23.550 --> 00:00:25.220
loss I could say that with authority
because I'm one of them so the reason my

00:00:25.220 --> 00:00:25.230
because I'm one of them so the reason my
 

00:00:25.230 --> 00:00:27.140
because I'm one of them so the reason my
lab studies this is because I actually

00:00:27.140 --> 00:00:27.150
lab studies this is because I actually
 

00:00:27.150 --> 00:00:29.060
lab studies this is because I actually
have alopecia areata and that's what

00:00:29.060 --> 00:00:29.070
have alopecia areata and that's what
 

00:00:29.070 --> 00:00:30.800
have alopecia areata and that's what
really sparked us to do this type of

00:00:30.800 --> 00:00:30.810
really sparked us to do this type of
 

00:00:30.810 --> 00:00:33.110
really sparked us to do this type of
work over 6 million people in the u.s.

00:00:33.110 --> 00:00:33.120
work over 6 million people in the u.s.
 

00:00:33.120 --> 00:00:35.000
work over 6 million people in the u.s.
also suffer from various forms of

00:00:35.000 --> 00:00:35.010
also suffer from various forms of
 

00:00:35.010 --> 00:00:36.350
also suffer from various forms of
alopecia areata so this is a

00:00:36.350 --> 00:00:36.360
alopecia areata so this is a
 

00:00:36.360 --> 00:00:38.540
alopecia areata so this is a
tremendously large and motivated

00:00:38.540 --> 00:00:38.550
tremendously large and motivated
 

00:00:38.550 --> 00:00:40.250
tremendously large and motivated
population of patients who have no other

00:00:40.250 --> 00:00:40.260
population of patients who have no other
 

00:00:40.260 --> 00:00:42.020
population of patients who have no other
treatments available treatment for this

00:00:42.020 --> 00:00:42.030
treatments available treatment for this
 

00:00:42.030 --> 00:00:43.970
treatments available treatment for this
disease in the past has been hit miss

00:00:43.970 --> 00:00:43.980
disease in the past has been hit miss
 

00:00:43.980 --> 00:00:47.240
disease in the past has been hit miss
with steroids and with varying degrees

00:00:47.240 --> 00:00:47.250
with steroids and with varying degrees
 

00:00:47.250 --> 00:00:48.190
with steroids and with varying degrees
of success

00:00:48.190 --> 00:00:48.200
of success
 

00:00:48.200 --> 00:00:51.080
of success
we've been excited to see data both in

00:00:51.080 --> 00:00:51.090
we've been excited to see data both in
 

00:00:51.090 --> 00:00:53.420
we've been excited to see data both in
mice and now in people to show that we

00:00:53.420 --> 00:00:53.430
mice and now in people to show that we
 

00:00:53.430 --> 00:00:55.790
mice and now in people to show that we
can reverse this disease with small

00:00:55.790 --> 00:00:55.800
can reverse this disease with small
 

00:00:55.800 --> 00:00:58.430
can reverse this disease with small
molecules that are aimed at reversing

00:00:58.430 --> 00:00:58.440
molecules that are aimed at reversing
 

00:00:58.440 --> 00:01:01.220
molecules that are aimed at reversing
the inflammatory condition in humans the

00:01:01.220 --> 00:01:01.230
the inflammatory condition in humans the
 

00:01:01.230 --> 00:01:03.290
the inflammatory condition in humans the
trough reversal in the treatment of

00:01:03.290 --> 00:01:03.300
trough reversal in the treatment of
 

00:01:03.300 --> 00:01:06.320
trough reversal in the treatment of
alopecia areata got started based on the

00:01:06.320 --> 00:01:06.330
alopecia areata got started based on the
 

00:01:06.330 --> 00:01:08.810
alopecia areata got started based on the
clinical a genetic and immunologic

00:01:08.810 --> 00:01:08.820
clinical a genetic and immunologic
 

00:01:08.820 --> 00:01:11.359
clinical a genetic and immunologic
discoveries made by doctors Christiano

00:01:11.359 --> 00:01:11.369
discoveries made by doctors Christiano
 

00:01:11.369 --> 00:01:12.429
discoveries made by doctors Christiano
and Klein's

00:01:12.429 --> 00:01:12.439
and Klein's
 

00:01:12.439 --> 00:01:14.929
and Klein's
in investigating the genetics of

00:01:14.929 --> 00:01:14.939
in investigating the genetics of
 

00:01:14.939 --> 00:01:17.240
in investigating the genetics of
alopecia areata they were able to then

00:01:17.240 --> 00:01:17.250
alopecia areata they were able to then
 

00:01:17.250 --> 00:01:19.550
alopecia areata they were able to then
subsequently pinpoint to several immune

00:01:19.550 --> 00:01:19.560
subsequently pinpoint to several immune
 

00:01:19.560 --> 00:01:21.410
subsequently pinpoint to several immune
pathways that appear to be important in

00:01:21.410 --> 00:01:21.420
pathways that appear to be important in
 

00:01:21.420 --> 00:01:23.690
pathways that appear to be important in
alopecia areata the next step was

00:01:23.690 --> 00:01:23.700
alopecia areata the next step was
 

00:01:23.700 --> 00:01:25.490
alopecia areata the next step was
identifying available drugs that

00:01:25.490 --> 00:01:25.500
identifying available drugs that
 

00:01:25.500 --> 00:01:28.070
identifying available drugs that
actually inhibit these pathways and this

00:01:28.070 --> 00:01:28.080
actually inhibit these pathways and this
 

00:01:28.080 --> 00:01:29.990
actually inhibit these pathways and this
is the basis upon which ruxolitinib was

00:01:29.990 --> 00:01:30.000
is the basis upon which ruxolitinib was
 

00:01:30.000 --> 00:01:32.690
is the basis upon which ruxolitinib was
selected once the drug was selected we

00:01:32.690 --> 00:01:32.700
selected once the drug was selected we
 

00:01:32.700 --> 00:01:36.670
selected once the drug was selected we
then went about designing a trial to

00:01:36.670 --> 00:01:36.680
then went about designing a trial to
 

00:01:36.680 --> 00:01:39.469
then went about designing a trial to
preliminary test its effect on alopecia

00:01:39.469 --> 00:01:39.479
preliminary test its effect on alopecia
 

00:01:39.479 --> 00:01:42.679
preliminary test its effect on alopecia
areata we now have the ability to

00:01:42.679 --> 00:01:42.689
areata we now have the ability to
 

00:01:42.689 --> 00:01:46.749
areata we now have the ability to
identify potential targets for treatment

00:01:46.749 --> 00:01:46.759
identify potential targets for treatment
 

00:01:46.759 --> 00:01:51.440
identify potential targets for treatment
and using what some people call a

00:01:51.440 --> 00:01:51.450
and using what some people call a
 

00:01:51.450 --> 00:01:53.630
and using what some people call a
mechanism driven approach that is to

00:01:53.630 --> 00:01:53.640
mechanism driven approach that is to
 

00:01:53.640 --> 00:01:57.410
mechanism driven approach that is to
look for pathways that are altered in

00:01:57.410 --> 00:01:57.420
look for pathways that are altered in
 

00:01:57.420 --> 00:02:01.130
look for pathways that are altered in
human disease and then to see if those

00:02:01.130 --> 00:02:01.140
human disease and then to see if those
 

00:02:01.140 --> 00:02:04.789
human disease and then to see if those
alterations lend themselves to some type

00:02:04.789 --> 00:02:04.799
alterations lend themselves to some type
 

00:02:04.799 --> 00:02:07.190
alterations lend themselves to some type
of manipulation either pharmacologically

00:02:07.190 --> 00:02:07.200
of manipulation either pharmacologically
 

00:02:07.200 --> 00:02:07.710
of manipulation either pharmacologically
or Jen

00:02:07.710 --> 00:02:07.720
or Jen
 

00:02:07.720 --> 00:02:10.950
or Jen
to clay or both and I think that's what

00:02:10.950 --> 00:02:10.960
to clay or both and I think that's what
 

00:02:10.960 --> 00:02:14.310
to clay or both and I think that's what
we have in the case of this study which

00:02:14.310 --> 00:02:14.320
we have in the case of this study which
 

00:02:14.320 --> 00:02:18.390
we have in the case of this study which
is an autoimmune disease that has eluded

00:02:18.390 --> 00:02:18.400
is an autoimmune disease that has eluded
 

00:02:18.400 --> 00:02:23.180
is an autoimmune disease that has eluded
for decades any basic understanding of

00:02:23.180 --> 00:02:23.190
for decades any basic understanding of
 

00:02:23.190 --> 00:02:27.420
for decades any basic understanding of
the development and the causation of the

00:02:27.420 --> 00:02:27.430
the development and the causation of the
 

00:02:27.430 --> 00:02:31.350
the development and the causation of the
disease we went on to show which immune

00:02:31.350 --> 00:02:31.360
disease we went on to show which immune
 

00:02:31.360 --> 00:02:33.330
disease we went on to show which immune
pathways might be important in the cell

00:02:33.330 --> 00:02:33.340
pathways might be important in the cell
 

00:02:33.340 --> 00:02:35.700
pathways might be important in the cell
death of the hair follicle and then

00:02:35.700 --> 00:02:35.710
death of the hair follicle and then
 

00:02:35.710 --> 00:02:37.650
death of the hair follicle and then
using those insights we blocked those

00:02:37.650 --> 00:02:37.660
using those insights we blocked those
 

00:02:37.660 --> 00:02:41.160
using those insights we blocked those
pathways in the mouse models showed they

00:02:41.160 --> 00:02:41.170
pathways in the mouse models showed they
 

00:02:41.170 --> 00:02:43.410
pathways in the mouse models showed they
were efficacious and then went on to go

00:02:43.410 --> 00:02:43.420
were efficacious and then went on to go
 

00:02:43.420 --> 00:02:47.160
were efficacious and then went on to go
on to try medically relevant antibodies

00:02:47.160 --> 00:02:47.170
on to try medically relevant antibodies
 

00:02:47.170 --> 00:02:49.920
on to try medically relevant antibodies
and small molecules to see whether when

00:02:49.920 --> 00:02:49.930
and small molecules to see whether when
 

00:02:49.930 --> 00:02:51.840
and small molecules to see whether when
we block these pathways we could reverse

00:02:51.840 --> 00:02:51.850
we block these pathways we could reverse
 

00:02:51.850 --> 00:02:53.820
we block these pathways we could reverse
the alopecia areata and we showed that

00:02:53.820 --> 00:02:53.830
the alopecia areata and we showed that
 

00:02:53.830 --> 00:02:56.370
the alopecia areata and we showed that
it was true in mouse models and then

00:02:56.370 --> 00:02:56.380
it was true in mouse models and then
 

00:02:56.380 --> 00:02:59.220
it was true in mouse models and then
went on to go to a small series of

00:02:59.220 --> 00:02:59.230
went on to go to a small series of
 

00:02:59.230 --> 00:03:00.690
went on to go to a small series of
patients and show that the therapies

00:03:00.690 --> 00:03:00.700
patients and show that the therapies
 

00:03:00.700 --> 00:03:03.270
patients and show that the therapies
could also be effective in people we are

00:03:03.270 --> 00:03:03.280
could also be effective in people we are
 

00:03:03.280 --> 00:03:06.720
could also be effective in people we are
very committed to making sure that that

00:03:06.720 --> 00:03:06.730
very committed to making sure that that
 

00:03:06.730 --> 00:03:08.190
very committed to making sure that that
patients with alopecia areata have

00:03:08.190 --> 00:03:08.200
patients with alopecia areata have
 

00:03:08.200 --> 00:03:10.980
patients with alopecia areata have
access to this class of drugs hopefully

00:03:10.980 --> 00:03:10.990
access to this class of drugs hopefully
 

00:03:10.990 --> 00:03:12.600
access to this class of drugs hopefully
in a way sauna day that's not an

00:03:12.600 --> 00:03:12.610
in a way sauna day that's not an
 

00:03:12.610 --> 00:03:14.759
in a way sauna day that's not an
off-label indication meaning we'd like

00:03:14.759 --> 00:03:14.769
off-label indication meaning we'd like
 

00:03:14.769 --> 00:03:17.520
off-label indication meaning we'd like
to pursue getting a label getting an

00:03:17.520 --> 00:03:17.530
to pursue getting a label getting an
 

00:03:17.530 --> 00:03:19.710
to pursue getting a label getting an
indication for a jak inhibitor in

00:03:19.710 --> 00:03:19.720
indication for a jak inhibitor in
 

00:03:19.720 --> 00:03:22.320
indication for a jak inhibitor in
alopecia areata we're deeply committed

00:03:22.320 --> 00:03:22.330
alopecia areata we're deeply committed
 

00:03:22.330 --> 00:03:23.970
alopecia areata we're deeply committed
to doing that there are so many other

00:03:23.970 --> 00:03:23.980
to doing that there are so many other
 

00:03:23.980 --> 00:03:27.000
to doing that there are so many other
diseases if you will ahead of us other

00:03:27.000 --> 00:03:27.010
diseases if you will ahead of us other
 

00:03:27.010 --> 00:03:28.860
diseases if you will ahead of us other
diseases that might be considered much

00:03:28.860 --> 00:03:28.870
diseases that might be considered much
 

00:03:28.870 --> 00:03:30.360
diseases that might be considered much
more life-threatening or life-altering

00:03:30.360 --> 00:03:30.370
more life-threatening or life-altering
 

00:03:30.370 --> 00:03:32.670
more life-threatening or life-altering
than alopecia can sometimes get pushed

00:03:32.670 --> 00:03:32.680
than alopecia can sometimes get pushed
 

00:03:32.680 --> 00:03:34.710
than alopecia can sometimes get pushed
to the backburner or to the bottom of

00:03:34.710 --> 00:03:34.720
to the backburner or to the bottom of
 

00:03:34.720 --> 00:03:36.630
to the backburner or to the bottom of
the list but this has been the major

00:03:36.630 --> 00:03:36.640
the list but this has been the major
 

00:03:36.640 --> 00:03:39.360
the list but this has been the major
focus of our entire group and we would

00:03:39.360 --> 00:03:39.370
focus of our entire group and we would
 

00:03:39.370 --> 00:03:40.979
focus of our entire group and we would
like very much to make sure that this

00:03:40.979 --> 00:03:40.989
like very much to make sure that this
 

00:03:40.989 --> 00:03:42.470
like very much to make sure that this
ball gets across the finish line

00:03:42.470 --> 00:03:42.480
ball gets across the finish line
 

00:03:42.480 --> 00:03:45.120
ball gets across the finish line
whatever that takes and hopefully we'll

00:03:45.120 --> 00:03:45.130
whatever that takes and hopefully we'll
 

00:03:45.130 --> 00:03:46.979
whatever that takes and hopefully we'll
be joining with some pharmaceutical

00:03:46.979 --> 00:03:46.989
be joining with some pharmaceutical
 

00:03:46.989 --> 00:03:49.080
be joining with some pharmaceutical
partners to make sure that alopecia

00:03:49.080 --> 00:03:49.090
partners to make sure that alopecia
 

00:03:49.090 --> 00:03:51.390
partners to make sure that alopecia
stays top of mind and that someday this

00:03:51.390 --> 00:03:51.400
stays top of mind and that someday this
 

00:03:51.400 --> 00:03:53.160
stays top of mind and that someday this
is an approved indication for jak

00:03:53.160 --> 00:03:53.170
is an approved indication for jak
 

00:03:53.170 --> 00:03:55.560
is an approved indication for jak
inhibitor

